Defining progression in non-IPF ILD
T. Goos (Leuven, Belgium), L. De Sadeleer (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), E. De Langhe (Leuven, Belgium), A. Dubbeldam (Leuven, Belgium), E. Verbeken (Leuven, Belgium), G. Verleden (Leuven, Belgium), M. Vermant (Leuven, Belgium), J. Verschakelen (Leuven, Belgium), R. Vos (Leuven, Belgium), B. Weynand (Leuven, Belgium), S. Verleden (Leuven, Belgium), W. Wuyts (Leuven, Belgium)
Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Goos (Leuven, Belgium), L. De Sadeleer (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), E. De Langhe (Leuven, Belgium), A. Dubbeldam (Leuven, Belgium), E. Verbeken (Leuven, Belgium), G. Verleden (Leuven, Belgium), M. Vermant (Leuven, Belgium), J. Verschakelen (Leuven, Belgium), R. Vos (Leuven, Belgium), B. Weynand (Leuven, Belgium), S. Verleden (Leuven, Belgium), W. Wuyts (Leuven, Belgium). Defining progression in non-IPF ILD. 2967
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: